A true high-tech platform dedicated to niche active pharmaceutical ingredients requiring complex chemistry and extensive technical expertise, ICROM is a trusted pharmaceutical CDMO partner for companies in the sector worldwide.
We specialise in bespoke development, process transfer and pharmaceutical scale-up, as well as in the GMP API manufacturing of complex, high-value-added small molecules and advanced intermediates.
La diversification maîtrisée des activités
L’intégration progressive de la chaîne de valeur pour des ingrédients robustes et innovants
L'internationalisation progressive.
Since 1969, ICROM Srl has embodied Italian pharmaceutical industrial expertise within the family-owned Proxis Développement group.
Specialising in the development and production of active pharmaceutical ingredients (APIs), ICROM operates as both:
La diversification maîtrisée des activités
L’intégration progressive de la chaîne de valeur pour des ingrédients robustes et innovants
L'internationalisation progressive.
A manufacturer of generic active ingredients
Pharmaceutical CDMO for the global pharmaceutical industry
Strategic CMC (Chemistry, Manufacturing and Controls) partner for innovative laboratories
ICROM’s business today is based on a balance between the production of generic APIs and high value-added CDMO projects, ensuring both industrial stability and a dynamic approach for innovation.
With over 50 years’ expertise in fine chemistry and industrialisation, ICROM has established itself as a leading European player in the production of complex small molecules and high-value-added active pharmaceutical ingredients. Today, ICROM supports over 200 global stakeholders in the pharmaceutical sector and offers 25 industrial-scale APIs, several of which are produced under exclusive licence.
ICROM IN PICTURES
Founded by Jean Epuran in 1969, ICROM began its operations as a CMO for Synthelabo (now Sanofi).
In 1996, its integration into the family-owned Moor Group marked a major strategic turning point for its development. This affiliation with our holding company enabled ICROM to accelerate its organisational development, boost its investments and consolidate its international positioning.
"
Thanks to our integration into Proxis Développement, our pharmaceutical division has undergone a profound transformation: expansion of the industrial site, modernisation of equipment and increased capacity for complex and highly active molecules. Today, our site in Italy now covers over 20,000 m² and constitutes an integrated pharmaceutical platform meeting international standards "
.webp)
Aline SASSI
CEO of ICROM
ICROM supports stakeholders in the pharmaceutical sector across the entire value chain for pharmaceutical active ingredients:
API development and process optimisation
Manufacture of new chemical entities (NCEs) to support clinical programmes
Industrial and commercial production of active pharmaceutical ingredients
CMC support and regulatory compliance
La diversification maîtrisée des activités
L’intégration progressive de la chaîne de valeur pour des ingrédients robustes et innovants
L'internationalisation progressive.
This integrated approach ensures every transition is managed effectively, from laboratory R&D to market launch.
By combining scientific excellence, expertise in GMP requirements and large-scale industrial capabilities, ICROM guarantees reliability, compliance and performance for demanding pharmaceutical projects.
In 2024, Proxis Development acquired Holodiag, a French CRO specialising in upstream research and analytical studies.
Its expertise perfectly complements ICROM’s industrial capabilities. Holodiag is a French service provider dedicated to solid-state pharmaceuticals and small-molecule crystallisation processes. With over 15 years’ experience, we support your projects through our analysis, screening and crystallisation process development services.
La diversification maîtrisée des activités
L’intégration progressive de la chaîne de valeur pour des ingrédients robustes et innovants
L'internationalisation progressive.
"
The integration of Holodiag into ICROM now enables the group to cover a broader spectrum: from upstream research through to the commercial production of active pharmaceutical ingredients, thereby offering clients enhanced scientific and industrial continuity. "
Pierric MARCHAND,
PhD, CEO of Holodiag
HOLODIAG in pictures
Driven by a five-year investment programme worth €30 million, ICROM achieved key milestones in 2025:
Commissioning of a new HP-API industrial unit dedicated to anti-cancer active pharmaceutical ingredients, produced in a contained environment
Opening of a R&D laboratory specifically dedicated to HP-APIs
Construction of a multi-purpose unit of over 100 m³ (to be completed over two years)
Expansion of the solvent storage facility (from 30 to 160 m³)
Creation of a new wastewater treatment plant
Installation of an RTO (regenerative thermal oxidiser) system
Presence of an ultra-pure water production unit
This equipment strengthens the site’s capacity to support its clients from clinical development through to GMP API manufacturing, in compliance with quality, safety and environmental performance standards.
Supported by Proxis Développement’s long-term vision, ICROM positions itself as a pharmaceutical CDMO capable of industrialising complex molecules, mastering the challenges of pharmaceutical scale-up and sustainably supporting the sector’s growth.
La diversification maîtrisée des activités
L’intégration progressive de la chaîne de valeur pour des ingrédients robustes et innovants
L'internationalisation progressive.
